Open Access795 Real World Safety of Vedolizumab and Anti-TNF Therapies in Biologic-Naïve Ulcerative Colitis and Crohn's Disease Patients: Results From the EVOLVE Study
Author(s) -
Andrés Yarur,
Gerassimos J. Mantzaris,
Uri Kopylov,
Marielle Bassel,
Neil R. Brett,
Trevor Lissoos,
Claudia Lopez,
Athanasios Natsios,
Christina Kifnidi,
Sumit Saha,
Dirk Demuth,
Haridarshan Patel,
Brian Bressler
Publication year - 2019
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000592716.59064.e9
Subject(s) - medicine , vedolizumab , infliximab , adalimumab , ulcerative colitis , discontinuation , hazard ratio , adverse effect , incidence (geometry) , golimumab , certolizumab pegol , inflammatory bowel disease , crohn's disease , surgery , confidence interval , disease , physics , optics